Vedere Bio II

Vedere Bio II was excited to be included as part of LabCentral's 238 Grand Opening. We even had some special guests visit our lab! #biotech #genetherapy #optogenetics

Today, Vedere Bio II announces that Russell Kelley, Ph.D., Managing Director of the @RD_Fund, will replace Benjamin Yerxa, Ph.D. as Board observer. We'd like to thank Ben for his valuable contributions to the Board and are honored to have Rusty join us!

Vedere Bio II is pleased to present positive new data supporting its proprietary platform at #ASGCT22! Read more here: #news" target="_blank" rel="nofollow noopener">vederebio.com/#news

Today, Vedere Bio II announced that we will present two abstracts at the 25th Annual @ASGCTherapy meeting. Learn more about what this means for the company here: #news" target="_blank" rel="nofollow noopener">vederebio.com/#news #ASGCT22

Vedere Bio II is pleased to welcome Anna Demetriades, M.D., PH.D. as Chief Medical Officer! Get a better view on the Vedere news here:#news" target="_blank" rel="nofollow noopener">vederebio.com/#news #biotech #genetherapy #optogenetics

Vedere Bio II is pleased to welcome Gina Consylman as Chief Financial Officer! Get a better view on the Vedere news here: #news" target="_blank" rel="nofollow noopener">vederebio.com/#news #biotech #genetherapy #optogenetics

Vedere Bio II is pleased to welcome Martina Schinke as Vice President, Program Leader! bit.ly/3sotESW #genetherapy #biotech #optogenetics

“@Vedere is proud to be included on the list of the 10 largest Series A financings of 2021 in Massachusetts biotech! bit.ly/3Fg7JSD #genetherapy #opthlamology #optogenetics

Vedere Bio II is pleased to welcome Michael Murtagh as Senior Vice President, Regulatory Affairs! #genetherapy #biotech #optogenetics

Vedere Bio II is pleased to welcome Meihua Ju, as Vice President, Preclinical! #genetherapy #biotech

Proud to partner with you again to bring next generation vision restoration treatments to patients. RD Fund: Where We’ve Been & Where We’re Going linkedin.com/feed/update/ur…

We are pleased to welcome Gabor Veres as Chief Scientific Officer! With 20 yrs of experience developing cell & #genetherapy products, Dr. Veres will provide invaluable counsel as we continue our work to rapidly restore vision to patients. bit.ly/3vQlG4u #biotech

Today, we are thrilled to announce the launch of Vedere Bio II! Vedere Bio II (Vedere) is pioneering beyond traditional #genetherapy to not just slow vision loss, but actually restore it. Read more here: #news" target="_blank" rel="nofollow noopener">vederebio.com/#news #bionews

Our President & CEO, Cyrus Mozayeni, spoke with @AlexWestchester from @GENbio! Read the interview here bit.ly/38PR0IQ, and take a deeper dive into what #optogenetics is, how @VedereBio came to be acquired by @Novartis, and future plans for Vedere Bio II!

#ICYMI: Yesterday @VedereBio was acquired by @Novartis #ophthalmology #bionews

Today @VedereBio is proud to announce the launch of Vedere Bio ll, our new ocular gene therapy company leveraging a toolbox to develop a pipeline of vision restoration and vision preservation therapies: vederebio.com #ophthalmology #bionews

Today @VedereBio announced we’ve been acquired by @Novartis. We’re excited to get our programs in the hands of an innovative company that will push forward our mission to deliver functional vision to patients in need. Details here: bit.ly/34BeoHq #ophthalmology #bionews